Liquid biopsy in pediatric acute lymphoblastic leukemia.
Blood-based liquid biopsy tests can track childhood leukemia in real time without bone marrow punctures, potentially reducing procedural burden in this common pediatric cancer.
This review comprehensively evaluates liquid biopsy modalities in pediatric ALL—the most common pediatric malignancy—covering ctDNA, cfDNA, circulating tumor cells, and exosome-based approaches for disease monitoring, MRD detection, and treatment response tracking. The synthesis highlights genuine potential for minimally invasive real-time disease monitoring to complement standard bone marrow evaluation and reduce procedural burden in this pediatric population.
What the study was
- Study design
- Narrative review
- Population
- Pediatric acute lymphoblastic leukemia patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Frontiers in oncology
Why it surfaced
Liquid biopsy in pediatric ALL represents a high-unmet-need area for minimally invasive monitoring; review summarizes emerging evidence relevant to pediatric oncology clinical trial design and MRD monitoring protocols.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.